SCHEMBL3574763

SCHEMBL3574763

C[C@H]1CCCN1CC1CCCN1C(=O)c1c(F)cc(OCc2cscn2)cc1F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.38
SCN1A P35498 2/20 0.36
SCN5A Q14524 2/20 0.36
SCN8A Q9UQD0 2/20 0.36
DPP4 P27487 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
HRH3 Q9Y5N1 4/20 0.35
KDM1A O60341 1/20 0.34
MET P08581 3/20 0.33
SPHK2 Q9NRA0 1/20 0.33
KMT2A Q03164 1/20 0.32
GRM5 P41594 1/20 0.32
MAPK14 Q16539 1/20 0.32
CYP3A4 P08684 1/20 0.32
PDE4B Q07343 1/20 0.32
KCNH2 Q12809 1/20 0.32
POLB P06746 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12993582 1.00 ALOX5 (0.38) ALOX5SCN1ASCN5ASCN8ADPP4
SCHEMBL3574764 1.00 ALOX5 (0.38) ALOX5SCN1ASCN5ASCN8ADPP4
SCHEMBL12993581 0.90 CPS1 (0.40) ALOX5SCN1ASCN5ASCN8AHRH3
SCHEMBL4662385 0.90 CPS1 (0.40) ALOX5SCN1ASCN5ASCN8AHRH3
SCHEMBL3586474 0.90 CPS1 (0.40) ALOX5SCN1ASCN5ASCN8AHRH3
SCHEMBL3586481 0.87 MET (0.42) HRH3MET
SCHEMBL3586478 0.87 MET (0.42) HRH3MET
SCHEMBL12102084 0.84 GRM5 (0.46) HRH3METSPHK2GRM5POLB
SCHEMBL3276455 0.84 GRM5 (0.46) HRH3METSPHK2GRM5POLB
SCHEMBL3276452 0.84 GRM5 (0.46) HRH3METSPHK2GRM5POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846950-B2 Histamine H3 receptor inhibitors, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2010-12-07 US claimed
EP-1805169-B1 HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2008-12-24 EP claimed
US-20080015235-A1 Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses JESUDASON CYNTHIA D 2008-01-17 US claimed
US-7846950-B2 Histamine H3 receptor inhibitors, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2010-12-07 US disclosed
US-20080015235-A1 Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses JESUDASON CYNTHIA D 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015235-A1 Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses HRH3, HRH4, HCRTR1 ALOX5 1625/4885SCN1A 966/4885SCN5A 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.